000			01882nam a2200193#a 4500
001			28029
003			NIH
005			20240614021356.0
008			240614s1929 xx 000 0 eng d
040			_aNIH _beng
100			_aDible, James Henry, _d1889-
245		0	_aRecent advances in bacteriology and the study of the infections
264		4	_c1929
300			_aviii, 363 p.: _billus; _c21cm
520			_aRapid identification (ID) and antimicrobial susceptibility testing (AST) of the causative agent(s) of bloodstream infections (BSIs) are essential for the prompt administration of an effective antimicrobial therapy, which can result in clinical and financial benefits. Immediately after blood sampling, empirical antimicrobial therapy, chosen on clinical and epidemiological data, is administered. When ID and AST results are available, the clinician decides whether to continue or streamline the antimicrobial therapy, based on the results of the in vitro antimicrobial susceptibility profile of the pathogen. The aim of the present study is to review and discuss the experimental data, advantages, and drawbacks of recently developed technological advances of culture-based and molecular methods for the diagnosis of BSI (including mass spectrometry, magnetic resonance, PCR-based methods, direct inoculation methods, and peptide nucleic acid fluorescence in situ hybridization), the understanding of which could provide new perspectives to improve and fasten the diagnosis and treatment of septic patients. Although blood culture remains the gold standard to diagnose BSIs, newly developed methods can significantly shorten the turnaround time of reliable microbial ID and AST, thus substantially improving the diagnostic yield.
650			_aBacteriology _aCommunicable Diseases
856			_uhttps://repository.nih.gov.my/handle/123456789/240 _3Repository
942			_cREF
999			_c28029 _d28029